SG11201810970WA - Anti-egfr antibody drug conjugates - Google Patents
Anti-egfr antibody drug conjugatesInfo
- Publication number
- SG11201810970WA SG11201810970WA SG11201810970WA SG11201810970WA SG11201810970WA SG 11201810970W A SG11201810970W A SG 11201810970WA SG 11201810970W A SG11201810970W A SG 11201810970WA SG 11201810970W A SG11201810970W A SG 11201810970WA SG 11201810970W A SG11201810970W A SG 11201810970WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- road
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 5
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- XDLMVUHYZWKMMD-UHFFFAOYSA-N 3-trimethoxysilylpropyl 2-methylprop-2-enoate Chemical compound CO[Si](OC)(OC)CCCOC(=O)C(C)=C XDLMVUHYZWKMMD-UHFFFAOYSA-N 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 abstract 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 abstract 1
- 244000077233 Vaccinium uliginosum Species 0.000 abstract 1
- 235000021014 blueberries Nutrition 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 01E111 11111 MEMO 0111111MIMIDIE MIME ill 1111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/214282 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: COWLES, Cristin H. et al.; Womble Carlyle San- CO7K 16/28 (2006.01) A61P 35/00 (2006.01) dridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia 30357 A61K 47/68 (2017.01) A61P 43/00 (2006.01) (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/036368 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 07 June 2017 (07.06.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/347,416 08 June 2016 (08.06.2016) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: ABBVIE INC. [US/US]; 1 North Waukegan Road, North Chicago, IL 60064 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: BOGHAERT, Erwin, R.; 4510 Springbrook GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Road, Pleasant Prairie, WI 53158 (US). SOUERS, An- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, drew, J.; 156 Blueberry Road, Libertyville, IL 60048 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, PHILLIPS, Andrew, C.; 519 Garfield Avenue, Liber- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, tyville, IL 60048 (US). JUDD, Andrew,S.; 138 Main- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, sail Drive, Grayslakc, IL 60030 (US). BRUNCKO, Milan; TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 31231 Prairie RidgeRoad, Green Oaks, IL 60048 (US). KM, ML, MR, NE, SN, TD, TG). = = = (54) Title: ANTI-EGFR ANTIBODY DRUG CONJUGATES = z\"40 R 12 ' OH N = R2 R', Z 28-- '# (Ha) 1 = _ = HN 0 N = R 1 R ill) = CI R1le Z 2b = = = R 0 OH N R2 R 13 # = = 2 'ri (11b) 1 R4 = HN 0 N R 1 = f R1 1 1 1a R ilb CI R 4 Il .4 1 2b N. Z #-.\" R• OH ei N R2 /1113) R' GC el 2 a oic) • 7 1 71' HN 0 N Il R 1 ei CI R11' R 11 b IN 11 N (57) : The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit _ Bc1-xL, including compositions and methods of using said ADCs. Formula (IIa), (llb), (IIc) [Continued on next page] WO 2017/214282 Al MIDEDIMOMMIMMEMODIOHOIDIEHEIHIMEMOIS Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) the Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662347416P | 2016-06-08 | 2016-06-08 | |
PCT/US2017/036368 WO2017214282A1 (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810970WA true SG11201810970WA (en) | 2019-01-30 |
Family
ID=59078219
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914060WA SG10201914060WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
SG11201810970WA SG11201810970WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914060WA SG10201914060WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
Country Status (21)
Country | Link |
---|---|
US (2) | US20190343961A1 (en) |
EP (2) | EP4104865A1 (en) |
JP (3) | JP2019521106A (en) |
KR (2) | KR20230035690A (en) |
CN (4) | CN109563168A (en) |
AU (1) | AU2017277517A1 (en) |
BR (1) | BR112018075636A2 (en) |
CA (1) | CA3027178A1 (en) |
CL (2) | CL2018003527A1 (en) |
CO (1) | CO2018013497A2 (en) |
CR (1) | CR20180614A (en) |
DO (2) | DOP2018000272A (en) |
EC (1) | ECSP19000157A (en) |
IL (3) | IL308054A (en) |
MX (2) | MX2018015286A (en) |
PE (1) | PE20190512A1 (en) |
PH (1) | PH12018502602A1 (en) |
RU (1) | RU2018147224A (en) |
SG (2) | SG10201914060WA (en) |
TW (2) | TW201806626A (en) |
WO (1) | WO2017214282A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018015280A (en) * | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anti-egfr antibody drug conjugates. |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CN111065623A (en) * | 2017-05-24 | 2020-04-24 | 德克萨斯州大学系统董事会 | Linker for antibody drug conjugates |
WO2020233174A1 (en) * | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | One-pot preparation process for antibody drug conjugate intermediate |
JP2022532918A (en) | 2019-05-20 | 2022-07-20 | ノバルティス アーゲー | MCL-1 Inhibitor Antibody-Drug Conjugate and Usage |
KR20210097627A (en) | 2020-01-30 | 2021-08-09 | 성균관대학교산학협력단 | Antibody-drug conjugate comprising immune checkpoint inhibitor and exosome secretion inhibitor and Pharmaceutical composition comprising the same |
US20230218778A1 (en) | 2020-05-19 | 2023-07-13 | Les Laboratoires Servier | Para-amino-benzyl linkers, process for their preparation and their use in conjugates |
CN116761635A (en) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | BCL-XL inhibitor antibody drug conjugates and methods of use thereof |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
CA3212850A1 (en) * | 2021-06-22 | 2022-12-29 | Frank DELFINO | Anti-egfrviii antibody drug conjugates and uses thereof |
CN117580846A (en) * | 2022-04-29 | 2024-02-20 | 石药集团中奇制药技术(石家庄)有限公司 | Compounds with liver targeted delivery effect and oligonucleotide conjugates thereof |
WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1726514A (en) | 1926-11-01 | 1929-08-27 | Firm Ferd Liebschner & Sohn | Picker for looms |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
DE68921982T4 (en) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF. |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
KR100787073B1 (en) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | Methods for producing modified glycoproteins |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
JP5356648B2 (en) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス, インコーポレイテッド | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
RU2489423C2 (en) | 2006-02-02 | 2013-08-10 | Синтарга Б.В. | Water-soluble analogues cc-1065 and their conjugates |
EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
CA2762877A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
TWI571466B (en) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN103987711B (en) * | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 8-carbamoyl-2-(2,3-disubstituted pyridines-6-base)-1,2,3,4-tetrahydro isoquinoline derivative as the inducer of apoptosis for treating cancer and immunity and autoimmune disease |
BR112014013526A8 (en) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | antibody-drug conjugates and related compounds, compositions and methods |
IN2014MN01488A (en) | 2011-12-23 | 2015-04-17 | Mersana Therapeutics Inc | |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
KR102433686B1 (en) | 2012-05-15 | 2022-08-19 | 씨젠 인크. | Self-stabilizing linker conjugates |
US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
JP6334553B2 (en) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス,インコーポレイティド | Protein-polymer-drug conjugate |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
TW202214691A (en) | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | Anti-egfr antibodies and antibody drug conjugates |
BR112017012377A2 (en) * | 2014-12-09 | 2018-04-24 | Abbvie Inc | antibody-drug conjugates with cell-permeable bcl-x1 inhibitors |
JP2018502839A (en) * | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Bcl-xL inhibitory compound and antibody drug conjugate containing the same |
CA2970155A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
-
2017
- 2017-06-07 EP EP22166591.2A patent/EP4104865A1/en active Pending
- 2017-06-07 MX MX2018015286A patent/MX2018015286A/en unknown
- 2017-06-07 RU RU2018147224A patent/RU2018147224A/en not_active Application Discontinuation
- 2017-06-07 CN CN201780048216.7A patent/CN109563168A/en active Pending
- 2017-06-07 US US16/308,463 patent/US20190343961A1/en not_active Abandoned
- 2017-06-07 BR BR112018075636-9A patent/BR112018075636A2/en unknown
- 2017-06-07 AU AU2017277517A patent/AU2017277517A1/en active Pending
- 2017-06-07 EP EP17731394.7A patent/EP3468996B1/en not_active Withdrawn - After Issue
- 2017-06-07 JP JP2018564215A patent/JP2019521106A/en active Pending
- 2017-06-07 TW TW106118952A patent/TW201806626A/en unknown
- 2017-06-07 CA CA3027178A patent/CA3027178A1/en active Pending
- 2017-06-07 CN CN202211269863.XA patent/CN116059394A/en active Pending
- 2017-06-07 CN CN202211269635.2A patent/CN116059201A/en active Pending
- 2017-06-07 CN CN202211269794.2A patent/CN116059202A/en active Pending
- 2017-06-07 SG SG10201914060WA patent/SG10201914060WA/en unknown
- 2017-06-07 KR KR1020237007108A patent/KR20230035690A/en active Application Filing
- 2017-06-07 CR CR20180614A patent/CR20180614A/en unknown
- 2017-06-07 KR KR1020197000330A patent/KR20190015526A/en active IP Right Grant
- 2017-06-07 TW TW111128039A patent/TW202320860A/en unknown
- 2017-06-07 WO PCT/US2017/036368 patent/WO2017214282A1/en unknown
- 2017-06-07 PE PE2018003191A patent/PE20190512A1/en unknown
- 2017-06-07 IL IL308054A patent/IL308054A/en unknown
- 2017-06-07 SG SG11201810970WA patent/SG11201810970WA/en unknown
-
2018
- 2018-12-07 IL IL263571A patent/IL263571A/en unknown
- 2018-12-07 MX MX2022007807A patent/MX2022007807A/en unknown
- 2018-12-07 DO DO2018000272A patent/DOP2018000272A/en unknown
- 2018-12-07 CL CL2018003527A patent/CL2018003527A1/en unknown
- 2018-12-10 PH PH12018502602A patent/PH12018502602A1/en unknown
- 2018-12-13 CO CONC2018/0013497A patent/CO2018013497A2/en unknown
-
2019
- 2019-01-03 EC ECSENADI2019157A patent/ECSP19000157A/en unknown
- 2019-08-09 CL CL2019002270A patent/CL2019002270A1/en unknown
-
2021
- 2021-09-10 US US17/447,362 patent/US20230077680A1/en active Pending
- 2021-12-13 JP JP2021201460A patent/JP2022058351A/en active Pending
-
2022
- 2022-03-02 IL IL291073A patent/IL291073A/en unknown
- 2022-09-09 DO DO2022000182A patent/DOP2022000182A/en unknown
-
2023
- 2023-08-10 JP JP2023130710A patent/JP2023166395A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
SG11201811193TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201811490XA (en) | Cd3 binding antibodies | |
SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201408261UA (en) | Syringe | |
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |